Navigation Links
Right first time: Pioneering new methods of drug manufacture
Date:11/11/2009

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations. Using self-assembled monolayers, the team has been able to show that crystals form into their desired product form with the correct shape and particle structure, without the usual problems of polymorphism which results in huge losses to the pharmaceutical sector each year.

"If you imagine the way that oil sits on top of water, that's similar to how the monolayer works," says Professor Kevin Roberts of University's Faculty of Engineering. "We've shown that we can produce a well-defined crystal structure using a self-assembled monolayer bound onto a metal substrate within a regular reactor. This is exciting stuff, because it's a relatively simple system, but could make a huge difference in the efficiency of drug manufacture."

One of the first stages of the crystallisation process is called nucleation. During nucleation, particles are introduced into a reactor to encourage the formation of crystals. However, the way in which this is currently carried out is difficult to control and can often lead to the wrong shape, size or structure of drug crystal, something which affects the usefulness and efficacy of the compound.

The new system proven to work by the Leeds team, working alongside Ana Kwokal from Croatian pharmaceutical company PLIVA, has shown that introducing a self-assembled monolayer a layer of self-organising molecules that is attractive to the substance being crystallised into a reactor enables consistent crystal formation.

Professor Roberts says: "Because this is a really simple solution to ensuring consistent crystallisation, it has huge potential commercially. Our next steps are to make sure it's just as efficient on an industrial scale."

This work draws on previous research and experimental systems developed through the Chemicals Behaving Badly II initiative, an Engineering and Physical Sciences Research Council (EPSRC) programme which includes universities and industrial partners.


'/>"/>

Contact: Clare Elsley
Clare@campuspr.co.uk
44-113-258-9880
University of Leeds
Source:Eurekalert

Related medicine news :

1. Physicians for Human Rights Offers Training in Crime Scene Documentation
2. Bright Horizons Named One of Boston Globe 100s Top Places to Work
3. Good Sleepers More Likely to Eat Right
4. Mom was right: Nice guys dont always finish last
5. Rights Tracker Completes Fundraising
6. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
7. Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody
8. AHIP Is Right, and May Be Low
9. Researchers discover mechanism that helps humans see in bright and low light
10. Go Healthy Secures Nationwide Distributorship Rights to Patented Drinking Water
11. Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article on CBCNews ... or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions for them. ... largely responsible for the problem both in Canada and the United States. Dr. Michael ...
(Date:5/27/2017)... NY (PRWEB) , ... May 27, 2017 , ... From ... and Oticon. The three-day event was held at the Marriott Syracuse Downtown Hotel ... with the hearing brand and network of independent hearing healthcare providers to help them ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... ... (SAB) met this week to review more than eighty-nine grant submissions all ... and emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the ... versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA ... to be the first in Arkansas to introduce the most powerful SCS system and ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one ... for Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, ... meats and cheeses featured in these refreshingly balanced recipes are packed with flavor, ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... SAN DIEGO , May 4, 2017  The ... Clinical and Scientific Meeting— OBP Medical , a leading ... announced the launch of a new extra-small size and ... ER-SPEC vaginal specula. Already available in small, ... sizes makes OBP Medical,s line of single-use lighted specula ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
(Date:5/3/2017)... May 3, 2017  Getinge, a leading global ... quality enhancement and cost efficiency within healthcare and ... of contemporary practice demonstrating that intra-aortic balloon counterpulsation ... critically ill patients. The single-center, retrospective, observational study ... volume MEGA ® 50cc intra-aortic balloon (IAB) ...
Breaking Medicine Technology: